A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Unresectable · Locally Advanced · Metastatic Cancers · Relapsed/Refractory Lymphomas
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 170 (planned)
- Started
- Nov 21, 2024
- Main results expected
- Oct 30, 2028
- Fully finished
- Oct 30, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1-Part 1A (Dose Finding)- Number of Participants With Dose Limiting Toxicities (DLTs)
Measured over: Initiation of study drug through 4 weeks
Phase 1 and 2 - Number of Participants With a Treatment-emergent Adverse Event
Measured over: Initiation of study drug through 30 days after the last dose (up to approximately 24 months)
Phase 2- Objective Response Rate (ORR)
Measured over: Initiation from study drug until disease progression (up to approximately 24 months)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06678659 · record last updated 2026-08-20 · checked 2026-11-09 15:47 UTC